# Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

> **NCT00003125** · PHASE2 · COMPLETED · sponsor: **Georgetown University** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer
- Esophageal Cancer
- Gastric Cancer
- Lung Cancer
- Pancreatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** ALVAC-CEA vaccine
- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** vaccinia-CEA vaccine

## Key facts

- **NCT ID:** NCT00003125
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2011-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003125, "Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00003125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*